JCS/T2D - We are advocates. We learn. We share. We inform.

Cigna's Bold Step Forward: Making Weight-Loss Medications More Accessible
Could a Gut Bacterium Help Transform Diabetes and Obesity Care?
CVS Shifts to Wegovy as Preferred Obesity Medication, Raising Questions About Access and Affordability
Eli Lilly Narrows Focus for Oral GLP-1 Naperiglipron
Eli Lilly’s Zepbound Outperforms Novo Nordisk’s Wegovy in Head-to-Head Weight Loss Study
EU Recommends Wegovy® Label Update for Heart Failure in Obesity
Lilly Adds High-Dose Zepbound to Self-Pay Program, Expands Access to All Approved Strengths
Lilly Expands Zepbound Access with Single-Dose Vials at Half Price
Lilly Expands Zepbound Vial Options, Lowers Prices for Self-Pay Patients
Lilly’s Oral GLP-1 Clears Key Trial as Pfizer Exits Race
Lilly’s Oral GLP-1 Falls Short of Expectations, Boosting Novo Nordisk
Lilly’s Oral GLP-1 Pill Shows Strong Phase 3 Results as Novo Submits Rival for FDA Approval
Lilly’s Oral GLP-1, Orforglipron, Shows Strong Results in Obesity and Diabetes Trials
Liraglutide Reduces BMI in Children Under 12 With Obesity, But Questions Remain
Novo Nordisk and Valo Health Expand AI-Powered Partnership to Address Cardiometabolic Diseases
Novo Nordisk Lowers Outlook, Names New CEO, and Restructures R&D
Novo Nordisk Strikes $550M RNA Deal with Replicate Bioscience
Novo Nordisk's Amycretin Shows 22% Weight Loss in Early Trial Results
Novo Nordisk's CagriSema Gains Momentum Amid Investor Optimism and Legal Scrutiny
Novo Nordisk’s CagriSema Falls Short of Investor Expectations Despite Promising Weight-Loss Results

Page 1 of 2

JCS/T2D - We are advocates. We learn. We share. We inform.

Cigna's Bold Step Forward: Making Weight-Loss Medications More Accessible

Could a Gut Bacterium Help Transform Diabetes and Obesity Care?

CVS Shifts to Wegovy as Preferred Obesity Medication, Raising Questions About Access and Affordability

Eli Lilly Narrows Focus for Oral GLP-1 Naperiglipron

Eli Lilly’s Zepbound Outperforms Novo Nordisk’s Wegovy in Head-to-Head Weight Loss Study

EU Recommends Wegovy® Label Update for Heart Failure in Obesity

Lilly Adds High-Dose Zepbound to Self-Pay Program, Expands Access to All Approved Strengths

Lilly Expands Zepbound Access with Single-Dose Vials at Half Price

Lilly Expands Zepbound Vial Options, Lowers Prices for Self-Pay Patients

Lilly’s Oral GLP-1 Clears Key Trial as Pfizer Exits Race

Lilly’s Oral GLP-1 Falls Short of Expectations, Boosting Novo Nordisk

Lilly’s Oral GLP-1 Pill Shows Strong Phase 3 Results as Novo Submits Rival for FDA Approval

Lilly’s Oral GLP-1, Orforglipron, Shows Strong Results in Obesity and Diabetes Trials

Liraglutide Reduces BMI in Children Under 12 With Obesity, But Questions Remain

Novo Nordisk and Valo Health Expand AI-Powered Partnership to Address Cardiometabolic Diseases

Novo Nordisk Lowers Outlook, Names New CEO, and Restructures R&D

Novo Nordisk Strikes $550M RNA Deal with Replicate Bioscience

Novo Nordisk's Amycretin Shows 22% Weight Loss in Early Trial Results

Novo Nordisk's CagriSema Gains Momentum Amid Investor Optimism and Legal Scrutiny

Novo Nordisk’s CagriSema Falls Short of Investor Expectations Despite Promising Weight-Loss Results

Articles

News

Contact Us

Search